Another active clinical trial (NCT03319459) enrolling patients affected by advanced solid tumors expressing EGFR, including CRC patients, is evaluating the effect of PB-derived allogeneic NK cell administration in combination with Cetuximab. Here, EGFR is linked to colorectal carcinoma.